Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H39O4.Na |
Molecular Weight | 414.5538 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@@]1(CC[C@@]2([H])[C@]3([H])C[C@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC([O-])=O
InChI
InChIKey=DUYSCILLIVEITB-ADQIWYCWSA-M
InChI=1S/C24H40O4.Na/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2;/h14-21,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15-,16+,17-,18+,19+,20+,21+,23-,24-;/m1./s1
DescriptionCurator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Hyodeoxycholic_acid | https://cdn2.hubspot.net/hub/150154/file-27656828-pdf/docs/atheronova-ahro-quarterly-update-04-05-2013.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10936612
Curator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Hyodeoxycholic_acid | https://cdn2.hubspot.net/hub/150154/file-27656828-pdf/docs/atheronova-ahro-quarterly-update-04-05-2013.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10936612
Hyodeoxycholic acid, also known as HDCA, is a secondary bile acid. Natural 6alpha-hydroxylated bile acids are receptor-specific activators of nuclear liver X receptor alpha (LXRalpha), a nuclear receptor regulating the expression of the cholesterol 7alpha-hydroxylase gene. AHRO-001 (Hyodeoxycholic acid) is in phase I clinical trials for the treatment of atherosclerosis. Through a complex signaling processes utilizing LXR receptors, the compound is designed to increase the efficiency of cholesterol efflux using the HDL cells, which act on all cholesterol in the arterial circulation as well as in the lipid core of plaque deposits in the artery walls. Use of AHRO-001 has shown no adverse effects on morbidity, mortality or toxicity and has been well tolerated at high doses.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10936612 |
|||
Target ID: CHEMBL4370 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527334 |
|||
Target ID: CHEMBL6196 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8244999 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3344 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16750434 |
3.44 mg/kg single, intraperitoneal dose: 3.44 mg/kg route of administration: Intraperitoneal experiment type: SINGLE co-administered: GENIPOSIDE|Isoniazid|Cholic acid |
HYODEOXYCHOLIC ACID plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.121 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16750434 |
3.44 mg/kg single, intraperitoneal dose: 3.44 mg/kg route of administration: Intraperitoneal experiment type: SINGLE co-administered: GENIPOSIDE|Isoniazid|Cholic acid |
HYODEOXYCHOLIC ACID plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
likely | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
weak | ||||
yes [Km 11.6 uM] | ||||
yes [Km 12 uM] | ||||
yes [Km 150.4 uM] | ||||
yes [Km 178.5 uM] | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Isolation and characterization of hyodeoxycholic-acid: UDP-glucuronosyltransferase from human liver. | 1991 Sep 1 |
|
Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans. | 1993 Apr |
|
Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. | 1993 Jan |
|
UGT2B23, a novel uridine diphosphate-glucuronosyltransferase enzyme expressed in steroid target tissues that conjugates androgen and estrogen metabolites. | 1999 Dec |
|
Hyodeoxycholic acid efficiently suppresses atherosclerosis formation and plasma cholesterol levels in mice. | 2001 Aug |
|
Effect of bile salts on colonic mucus secretion in isolated vascularly perfused rat colon. | 2001 Jun |
|
Hydrophilic and hydrophobic bile acids exhibit different cytotoxicities through cytolysis, interleukin-8 synthesis and apoptosis in the intestinal epithelial cell lines. IEC-6 and Caco-2 cells. | 2001 May |
|
[Study on effect of qingkailing injection and its active principle in inducing cell apoptosis in human acute promyelocytic leukemia]. | 2001 Nov |
|
Dietary bile acids inhibit potentially elemental diet-induced small intestinal atrophy in rats. | 2002 Nov |
|
Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. | 2003 Aug 29 |
|
Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7. | 2003 Feb 1 |
|
Steroids in the intestinal tract of rats are affected by dietary-fibre-rich barley-based diets. | 2003 Nov |
|
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. | 2003 Nov |
|
UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. | 2004 |
|
Identification of UGT2B9*2 and UGT2B33 isolated from female rhesus monkey liver. | 2004 Jun 1 |
|
[Study on extraction technique of HDCA]. | 2004 May |
|
Effects of ileo-rectal anastomosis on cholesterol metabolism in pigs fed either casein or extruded soya beans. | 2004 May |
|
Effect of dried plums on colon cancer risk factors in rats. | 2005 |
|
Interfacial properties of most monofluorinated bile acids deviate markedly from the natural congeners: studies with the Langmuir-Pockels surface balance. | 2005 Mar |
|
Simultaneous determination of major bioactive components in Qingkailing injection by high-performance liquid chromatography with evaporative light scattering detection. | 2005 Nov |
|
[Simultaneous determination of five groups of components in qingkailing injection by high performance liquid chromatography with photo diode array detector and evaporative light scattering detector]. | 2005 Sep |
|
Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. | 2006 Apr |
|
3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats. | 2006 Jul 15 |
|
Isolation and determination of bile acids. | 2006 Jul-Sep |
|
Determination of three bile acids in artificial Calculus Bovis and its medicinal preparations by micellar electrokinetic capillary electrophoresis. | 2006 Jun 6 |
|
Simultaneous determination of nine components in Qingkailing injection by HPLC/ELSD/DAD and its application to the quality control. | 2006 Mar 3 |
|
Resistance to ursodeoxycholic acid-induced growth arrest can also result in resistance to deoxycholic acid-induced apoptosis and increased tumorgenicity. | 2006 Sep 1 |
|
Simultaneous determination of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rat serum for the pharmacokinetic investigations by high performance liquid chromatography-tandem mass spectrometry. | 2006 Sep 14 |
|
[Determination of chyodeoxycholic acid in Bile Arisaema by HPLC-ELSD]. | 2007 Aug |
|
Comparative study on major bioactive components in natural, artificial and in-vitro cultured Calculus Bovis. | 2007 Jan |
|
Use of selected chemical markers in combination with a multiple regression model to assess the contribution of domesticated animal sources of fecal pollution in the environment. | 2007 Nov |
|
Biotransformation of lithocholic acid by rat hepatic microsomes: metabolite analysis by liquid chromatography/mass spectrometry. | 2008 Feb |
|
Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction. | 2008 Sep |
|
Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs. | 2009 |
|
Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. | 2009 Dec |
|
Improved analysis of bile acids in tissues and intestinal contents of rats using LC/ESI-MS. | 2009 Jan |
|
The inhibitory effects of cholalic acid and hyodeoxycholalic acid on the expression of TNFalpha and IL-1beta after cerebral ischemia in rats. | 2009 Jan |
|
Bear bile: dilemma of traditional medicinal use and animal protection. | 2009 Jan 12 |
|
Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. | 2009 Jul 7 |
|
3-ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acid. | 2009 Sep |
|
Consumption of some polyphenols reduces fecal deoxycholic acid and lithocholic acid, the secondary bile acids of risk factors of colon cancer. | 2009 Sep 23 |
|
Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride. | 2010 |
|
Chemical genetic screen identifies lithocholic acid as an anti-aging compound that extends yeast chronological life span in a TOR-independent manner, by modulating housekeeping longevity assurance processes. | 2010 Jul |
|
Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol. | 2010 Mar |
|
Regulation of bile acid synthesis by fat-soluble vitamins A and D. | 2010 May 7 |
|
Voluntary wheel running exercise and dietary lactose concomitantly reduce proportion of secondary bile acids in rat feces. | 2010 Sep |
|
Inhibition of human UGT2B7 gene expression in transgenic mice by the constitutive androstane receptor. | 2011 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01931241
Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23752203
HDCA treatment (50 and 100 uM) significantly increased the expression of ATP-binding cassette subfamily A member 1 (Abca1), ATP-binding cassette subfamily G member 1 (Abcg1), and apolipoprotein E (Apoe) in RAW cells in a dose-response way.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID60908871
Created by
admin on Fri Dec 15 15:23:55 GMT 2023 , Edited by admin on Fri Dec 15 15:23:55 GMT 2023
|
PRIMARY | |||
|
23720132
Created by
admin on Fri Dec 15 15:23:55 GMT 2023 , Edited by admin on Fri Dec 15 15:23:55 GMT 2023
|
PRIMARY | |||
|
HBY71R8HO2
Created by
admin on Fri Dec 15 15:23:55 GMT 2023 , Edited by admin on Fri Dec 15 15:23:55 GMT 2023
|
PRIMARY | |||
|
DBSALT002661
Created by
admin on Fri Dec 15 15:23:55 GMT 2023 , Edited by admin on Fri Dec 15 15:23:55 GMT 2023
|
PRIMARY | |||
|
10421-49-5
Created by
admin on Fri Dec 15 15:23:55 GMT 2023 , Edited by admin on Fri Dec 15 15:23:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD